Search results for: Mikel Berdud
Filter search results
OHE at the 2019 International Health Economics Association (iHEA) World Congress
5 July 2019
…Koonal Shah, Mikel Berdud, and Olga Rozanova will be attending to present work from some of OHE’s projects. Understanding Shortages in the UK Generics Market In this session, Adrian…
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
…prices in many countries. The question then arises as to what should be a reasonable price for an orphan drug? The research by OHE authors Mikel Berdud and Adrian…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
Berdud, Drummond and Towse (2020) propose a method for establishing a reasonable price for an orphan drug. Assuming prices for drugs are set according to incremental value, they propose adjustments…
OHE at ISPOR Europe 2023
13 November 2023, 12:00am
…Discussion Period: 9:00 -10:00 Poster Session Pricing Pharmaceuticals for the Common Good: Is Value-Based Pricing Still the Right Solution? Eleanor Bell (panellist) Mikel Berdud (moderator) 08:00 – 09:00 Issue Panel…
OHE at ISPOR Europe 2024
17 November 2024, 8:00am
…Panel Innovative Pricing and Payment Schemes for Health Technologies: Fine in Theory, but How to Make Them Work in Practice? Mikel Berdud (panelist) 10:15-11:15 Issue Panel Balancing Budgets and Breakthroughs:…
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
…high prices in many countries. The question then arises as to what should be a reasonable price for an orphan drug? The research by OHE authors Mikel Berdud and Adrian…
Virtual ISPOR European 2020
10 November 2020
…registered attendees Mikel Berdud, PhD, MSc Senior Principal Economist, Office of Health Economics Panellist of ISPOR Europe Issue Panel In the session the panel discussed the implications of setting CETs…
OHE at the 2019 Spanish Health Economics Association (AES) Conference
5 June 2019
…of innovative medicines: the case of risperidone and second-generation antipsychotics This study, co-authored by Mikel Berdud, Bernarda Zamora, and Adrian Towse, aims to guide access decisions and drive the discussion…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…analysis by Wilsdon et al. (2022), the BEAM Alliance (2023), Dubios et al. (2022) and Berdud et al. (2019) supporting the “for” side whereas Ardal et al. (2023) , Van de Wiele et al. (2023) and The Non-Paper (2022) summarising…